Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with Type 2 diabetes

被引：0
|
作者：
Taylor, K [1 ]
Kim, D [1 ]
Bicsak, T [1 ]
Heintz, S [1 ]
Varns, A [1 ]
Aisporna, M [1 ]
Fineman, M [1 ]
Baron, A [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
123
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [41] Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type 1 Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy
    Herrmann, Kathrin
    Frias, Juan P.
    Edelman, Steven V.
    Lutz, Karen
    Shan, Kevin
    Chen, Steven
    Maggs, David
    Kolterman, Orville G.
    POSTGRADUATE MEDICINE, 2013, 125 (03) : 136 - 144
  • [42] Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
    Bode, Bruce W.
    Johnson, Joseph A.
    Hyveled, Liselotte
    Tamer, Soren C.
    Demissie, Marek
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (01) : 25 - +
  • [43] Twenty-eight day dose-response study with exenatide (synthetic exendin-4) in subjects with type 2 diabetes treated with metformin or with diet and exercise
    Poon, TH
    Nelson, P
    Love, K
    Shen, L
    Bicsak, TA
    Taylor, K
    Kim, DD
    DIABETES, 2004, 53 : A142 - A142
  • [44] The effect of continuous subcutaneous insulin infusion(CSII) on glucose metabolism and induction of long-term glycemic control in newly diagnosed type 2 diabetic patients
    Li, YB
    Xu, W
    Liao, ZH
    Yao, B
    Huang, ZM
    Weng, JP
    DIABETES, 2004, 53 : A112 - A112
  • [45] Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic control in type 2 diabetes
    Ehlers, MRW
    Harley, RE
    Schneider, RL
    Kipnes, MS
    DIABETES, 2002, 51 : A579 - A579
  • [46] Loss of glycemic control over time after infusion line change in patients with type 1 diabetes treated with continuous subcutaneous insulin infusions.
    Thethi, T. K.
    Outland, J.
    Malik, T.
    Fonseca, V. A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S296 - S296
  • [47] THE EFFECT OF LONG-TERM USE OF U-500 INSULIN VIA CONTINUOUS SUBCUTANEOUS INFUSION ON DURABILITY OF GLYCEMIC CONTROL AND WEIGHT IN OBESE, INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES
    Lane, Wendy S.
    Weinrib, Stephen L.
    Rappaport, Jonathan M.
    Hale, Christopher B.
    Farmer, Lynley K.
    Lane, Rebecca S.
    ENDOCRINE PRACTICE, 2013, 19 (02) : 196 - 201
  • [48] Good Glycemic Control Is Positively Associated with the Levels of Serum Albumin and Postprandial C-Peptide after Long-Term Continuous Subcutaneous Insulin Infusion Treatment in Patients with Type 2 Diabetes
    Choi, Soo-Bong
    Noh, Yun-Hee
    Lee, Jun-Ho
    Lee, Ju-Han
    Kim, Seonguk
    DIABETES, 2011, 60 : A590 - A590
  • [49] Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion
    Noh, Yun-Hee
    Lee, Se-Myung
    Kim, Eun-Ju
    Lee, Hyunil
    Lee, Jun-Ho
    Lee, Ju-Han
    Park, So-Young
    Koo, Ja-Hyun
    Wang, Jun-Ho
    Lim, In-Ja
    Choi, Soo-Bong
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2008, 24 (05) : 384 - 391
  • [50] Noninferiority Effects on Glycemic Control and β-Cell Function Improvement in Newly Diagnosed Type 2 Diabetes Patients: Basal Insulin Monotherapy Versus Continuous Subcutaneous Insulin Infusion Treatment
    Zeng, Longyi
    Lu, Hongyun
    Deng, Hongrong
    Mu, Panwei
    Li, Xiaofeng
    Wang, Manman
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (01) : 35 - 42
12345